[Webinar] From Bench to Bedside: Modeling Autoimmune, Genetic, and Fibrotic Kidney Diseases in Mice

The development of innovative therapeutics for renal diseases has moved from symptomatic treatments to disease-modifying treatments thanks to deeper understandings of the disease biology and precision medicine. The right preclinical animal models can significantly increase the translatability of preclinical data and therefore plays a critical role in the drug discovery process. To address this, GemPharmatech has developed a comprehensive portfolio of kidney disease models recapitulating autoimmune, genetic and fibrotic pathologies for diverse renal disease research. By reproducing key pathogenic drivers — B cell activation, complement cascades, monogenic variants and renal fibrosis — this differentiated pharmacodynamic platform supports the evaluation of multiple therapeutic modalities, including antibodies, fusion proteins, gene therapy and small molecule compounds. It facilitates the preclinical assessment and clinical translation of drug candidates for renal diseases, and supports the development of targeted therapies. Topics for this webinar include: 1. Scenarios for Evaluating Autoimmune, Genetic and Fibrotic Kidney Disease Models 2. ADPKD as a Case Study: Model Construction Strategy and Phenotypic Characterization 3. Applications of ADPKD Models Including Antibodies, Oligonucleotides and Beyond